Drug Development

Celgene’s Revlimid flops in Phase III lymphoma study, shares slide

Shares of Celgene were dinged Monday evening after the Big Biotech noted that its top franchise drug Revlimid didn’t make the cut as a maintenance therapy for diffuse large B-cell lymphoma (DLBCL).

While the drug hit the primary endpoint for progression-free survival compared to a placebo in the Phase III REMARC study, investigators at the Lymphoma Academic Research Organization in France say it failed to make a significant difference in overall survival. As a result, Celgene says it’s dropping plans for a regulatory filing.

Celgene stock dropped 2.5% in after market trading. LYSARC did the study under a research contract for Celgene.

Michael Pehl, Celgene President of Global Hematology and Oncology

Michael Pehl, Celgene President of Global Hematology and Oncology

Celgene isn’t done yet trying to expand the market for its $6 billion drug, though. The company says it’s continuing Phase III studies for non-Hodgkin lymphomas. Revlimid is used for multiple myeloma. Said Michael Pehl, the president of hematology and oncology at Celgene:

“We are continuing to partner with LYSA to complete the analyses of the REMARC study. We remain committed to finishing the four ongoing phase III trials evaluating Revlimid and are confident about its potential as a treatment option across different settings in lymphoma.”

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy